Clinical Trial Update: Metronomic PLD in Patients With Primary Endocrine Resistant ABC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for metronomic pegylated liposomal doxorubicin (PLD) in patients with primary endocrine-resistant advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• metronomic PLD (pegylated liposomal doxorubicin)

Snippet

Sponsor: Fudan University | Conditions: Advanced Breast Cancer | Phase 2 | Status: UNKNOWN